Pomalyst Dosage

Generic name: pomalidomide
Dosage form: capsule

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Multiple Myeloma

Females of reproductive potential must have negative pregnancy testing and use contraception methods before initiating POMALYST [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)].

The recommended starting dose of POMALYST is 4 mg once daily orally on Days 1-21 of repeated 28-day cycles until disease progression. POMALYST may be given in combination with dexamethasone [see Clinical Studies (14.1)].

POMALYST may be taken with water. Inform patients not to break, chew, or open the capsules. POMALYST should be taken without food (at least 2 hours before or 2 hours after a meal).

Dose Adjustments for Toxicities

Table 1: Dose Modification Instructions for POMALYST for Hematologic Toxicities
ANC, absolute neutrophil count.
  Toxicity   Dose Modification
  Neutropenia
  • ANC <500 per mcL or febrile neutropenia (fever more
    than or equal to 38.5°C and ANC <1,000 per mcL)

  • ANC return to more than or equal to 500 per mcL

  • Interrupt POMALYST treatment, follow CBC weekly




  • Resume POMALYST treatment at 3 mg daily
  • For each subsequent drop <500 per mcL


  • Return to more than or equal to 500 per mcL

  • Interrupt POMALYST treatment


  • Resume POMALYST treatment at 1 mg less than the previous dose
  Thrombocytopenia
  • Platelets <25,000 per mcL

  • Platelets return to >50,000 per mcL

  • Interrupt POMALYST treatment, follow CBC weekly

  • Resume POMALYST treatment at 3 mg daily
  • For each subsequent drop <25,000 per mcL

  • Return to more than or equal to 50,000 per mcL

  • Interrupt POMALYST treatment

  • Resume POMALYST treatment at 1 mg less than previous dose

For other Grade 3 or 4 toxicities, hold treatment and restart treatment at 1 mg less than the previous dose when toxicity has resolved to less than or equal to Grade 2 at the physician’s discretion.

To initiate a new cycle of POMALYST, the neutrophil count must be at least 500 per mcL and the platelet count must be at least 50,000 per mcL. If toxicities occur after dose reductions to 1 mg, then discontinue POMALYST.

2.3 Dose Adjustment for Strong CYP1A2 Inhibitors in the Presence of Strong CYP3A4 and P-gp Inhibitors

Avoid co-administration of strong inhibitors of CYP1A2. If necessary to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of CYP3A4 and P-gp, reduce POMALYST dose by 50%. No clinical efficacy or safety data exist [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].

Hide
(web2)